NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma.

This study is NOT currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

18-C-0138

Sponsoring Institute

National Cancer Institute (NCI)

Recruitment Detail

Type: No longer recruiting/follow-up only
Gender: Male & Female
Min Age: 18 Years
Max Age: N/A

Referral Letter Required

No

Population Exclusion(s)

Fetuses;
Pregnant Women;
Children

Keywords

Hereditary Cancer Disease;
Germline VHL Alteration;
Small Molecule Inhibitor of HIF-2a

Recruitment Keyword(s)

None

Condition(s)

Clear Cell Renal Cell Carcinoma

Investigational Drug(s)

PT2977

Investigational Device(s)

None

Intervention(s)

Drug: PT2977

Supporting Site

National Cancer Institute

Background:

Von Hippel-Lindau (VHL) disease-associated renal cell carcinomas are kidney tumors. They are associated with a rare genetic disorder. The drug PT2977 (belzutifan) blocks the action of a certain protein that is often overactive in these types of tumors. Researchers think the drug might help treat people with these tumors.

Objective:

To test how PT2977 (belzutifan) affects tumors in people with VHL disease-associated kidney cancer. To see if the drug has side effects.

Eligibility:

People ages 18 and older with VHL disease-associated kidney cancer

Design:

Participants will be screened with:

Medical and medication history

Physical exam

Questions about how well they are able to do normal activities

Biopsy results and tissue sample. If they do not have a sample, participants may need to have a new biopsy.

Heart and blood tests

Eye exam

Semen samples for male participants

CT scan, MRI, or ultrasound: Participants will lie on a table. A machine will take pictures of the body.

Participants will have visits every other week for the first 5 weeks, then every 4 weeks for the next 5 visits, and then every 12 weeks. Visits include repeats of screening tests.

Participants will receive a supply of the study drug at each visit to take at home. They will take 3 tablets by mouth daily.

Participants will continue treatment until they can no longer tolerate it or their disease gets worse.

Participants will have a final study visit 28 days after they take their last dose of study drug. This will include repeats of screening tests.

Participants may be contacted every 6 months for a period of up to 3 years after the study.

--Back to Top--

Eligibility

Eligibility:

-18 years of age or older with ability to understand and willingness to sign a written informed consent

-Diagnosis of von Hippel-Lindau disease, based on a germline VHL alteration

-At least 1 measurable solid RCC tumor and no RCC tumor greater than 3.0 cm that requires immediate surgical intervention. The diagnosis of RCC can be radiologic (histologic diagnosis not required). Patients may have VHL disease-associated tumors in other organ systems.


--Back to Top--

Citations:

Not Provided

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

Ramaprasad Srinivasan, M.D.
National Cancer Institute (NCI)
NIHBC 10 - CRC BG RM 2-5950
10 CENTER DR
BETHESDA MD 20892
(240) 760-6251
ramasrin@mail.nih.gov

Brooksley Augustine
National Cancer Institute (NCI)
National Institutes of Health
Building 10
Room 8D53
10 Center Drive
Bethesda, Maryland 20892
(240) 858-3197
brooke.augustine@nih.gov

NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office
1-888-NCI-1937

Clinical Trials Number:

NCT03401788

--Back to Top--